Diuretic prescriptions in the first year of haemodialysis: international practice patterns and associations with outcomes.

Abstract

The use of diuretics in patients on haemodialysis (HD) is thought to maintain diuresis. However, this assumption and the optimal dose are based on little scientific evidence, and associations with clinical outcomes are unclear. We reported international variations in diuretic use and loop diuretic dose across 27759 HD patients with dialysis vintage <1year in the Dialysis Outcomes and Practice Patterns Study phases 2-5 (2002-2015), a prospective cohort study. Doses of torsemide (4:1) and bumetanide (80:1) were converted to oral furosemide-equivalent doses. Adjusted Cox, logistic and linear regressions were used to investigate the association of diuretic use and dose with outcomes. Diuretic utilization varied widely by country at vintage <3months, ranging from >80% in Germany and Sweden to <35% in the USA, at a median dose ranging from 400-500mg/day in Germany and Sweden to <100mg/day in Japan and the USA. Neither diuretic use nor higher doses were associated with a lower risk of all-cause mortality, a higher risk of hospitalization for fracture or elevated parathyroid hormone levels, but the prescription of higher doses (>200mg/day) was associated with a higher risk of all-cause hospitalization. Substantial international differences exist in diuretic prescriptions, with use and doses much higher in some European countries than the USA. The prescription and higher doses of loop diuretics was not associated with improved outcomes.